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ABSTRACT  
OPA1 is the major gene responsible for Dominant Optic Atrophy (DOA) and the syndromic form 
DOA “plus”. Over 370 OPA1 mutations have been identified so far, although their pathogenicity is 
not always clear. We have analyzed one novel and a set of known OPA1 mutations to investigate 
their impact on protein functions in primary skin fibroblasts and in two “ad hoc” generated cell 
systems: the MGM1/OPA1 chimera yeast model and the Opa1-/- MEFs model expressing the 
mutated human OPA1 isoform 1. The yeast model allowed us to confirm the deleterious effects of 
these mutations and to gain information on their dominance/recessivity. The MEFs model enhanced 
the phenotypic alteration caused by mutations, nicely correlating with the clinical severity observed 
in patients, and suggested that the DOA “plus” phenotype could be induced by the combinatorial 
effect of mitochondrial network fragmentation with variable degrees of mtDNA depletion. Overall, 
the two models proved to be valuable tools to functionally assess and define the deleterious 
mechanism and the pathogenicity of novel OPA1 mutations, and useful to testing new therapeutic 
interventions. 
 
 
Keywords: OPA1 mutations, Dominant Optic Atrophy (DOA), OPA1, mitochondrial 
network, mtDNA, mitochondrial functions  
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1. INTRODUCTION 
Dominant optic atrophy (DOA) is one of the most common inherited optic neuropathies, 
characterized by degeneration of the retinal ganglion cells, leading to optic nerve atrophy and 
ultimately to blindness [1,2] . Most DOA patients harbor mutations in the OPA1 gene [3,4] 
encoding the mitochondrial GTPase OPA1, localized in the inner mitochondrial membrane [5]. This 
protein displays a mitochondrial-targeting sequence, a predicted transmembrane domain, followed 
by the three highly conserved regions: the GTPase, the middle and the GTPase effector domains. 
Eight OPA1 variants are present in humans, undergoing proteolytic cleavage by YME1L and 
OMA1 proteases [6] and generating a mixture of long and short isoforms (l- and s-forms) anchored 
to the inner membrane or soluble, respectively [7,8]. 
Currently, over 370 OPA1 gene variants have been identified, of which 65% is considered 
pathogenic. About 50% of the pathogenic variants cause the premature truncation of the open 
reading frame [9], supporting haploinsufficiency as the main pathological mechanism of the 
disease. The missense variants, mostly clustered in the GTPase domain and envisaged to exert a 
dominant-negative effect [10], are associated with high risk to developing the severe multisystem 
disorder DOA “plus” characterized by additional extraocular features, including sensorineural 
deafness, ataxia, myopathy, chronic progressive external ophthalmoplegia, peripheral neuropathy, 
multiple sclerosis-like features and parkinsonism/dementia [11–15]. More recently, severe clinical 
phenotypes, ranging from Behr to Leigh syndromes, have been associated with compound 
heterozygosity of OPA1 mutations, frequently in combination with the I382M hypomorphic allele, 
or homozygous OPA1 mutations qualifying as recessive forms [16–20]. 
Different degrees of mitochondrial network fragmentation and cristae disorganization have been 
reported in fibroblasts [11,21–24] and skeletal muscle from DOA patients [11], as well as in DOA 
mouse models [25–27].  
Phosphorus magnetic resonance spectroscopy revealed in vivo defective oxidative phosphorylation 
(OXPHOS) with reduced ATP production in muscle of DOA patients with several nonsense and 
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missense OPA1 mutations [28,29]. Dysfunctions of the energetic metabolism, i.e. decreased ATP 
synthesis rate, respiratory complexes activities, oxygen consumption and membrane potential were 
also documented in fibroblasts and lymphoblasts of patients carrying different OPA1 mutations 
[21,23,24,30].  
Mitochondrial DNA (mtDNA) depletion was never reported in fibroblasts or skeletal muscles of 
DOA and DOA “plus” patients [11,12,24,31], showing rather increased mtDNA copy number in 
COX-negative fibers [13]. Conversely, mtDNA deletions, initially associated with the severe DOA 
“plus” phenotype only [11,31], were subsequently reported in skeletal muscles of the majority of 
patients harboring OPA1 mutations, even in those with non-syndromic DOA [29]. Only recently, 
the identification of families with truly recessive OPA1 mutations and affected with a multisystem 
disorder, documented the occurrence of mtDNA depletion in skeletal muscle [18]. 
It is noteworthy that primary skin fibroblasts derived from patients bearing OPA1 mutations 
represent an important cell model for studying DOA pathophysiology, even if they often reveal a 
rather mild phenotype, likely as a consequence of the hemizygous transmission of DOA and the 
type/position of the mutation. Therefore, cell models avoiding the partial compensatory effect of the 
wild-type allele would enhance the defective phenotypic profile of the pathogenic OPA1 mutant 
allele. To this end, we developed two different cell models. The first is the Mgm1/OPA1 chimera 
yeast model, that has been previously described in detail [32]. The second takes advantage of Opa1-
/- mouse embryonic fibroblasts (MEFs), where human OPA1 isoform 1 (ISO1) bearing OPA1 
mutations was expressed.  The strength of these two models is that they are designed to provide 
complementary and non-overlapping information, thus allowing for a quick and comprehensive 
analysis of OPA1 mutations pathophysiology.  Here we present the detailed molecular and 
functional characterization of fibroblasts, MEFs and MGM1/OPA1 chimeras, demonstrating a 
faithful genotype/phenotype correlation, associating the DOA “plus” phenotype with a 
combinatorial effect of mitochondrial network fragmentation and mtDNA depletion, and validating 
a novel OPA1 mutation.  
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2. MATERIALS AND METHODS 
2.1. Plasmid construction and retroviral transduction  
Plasmid expressing the OPA1 isoforms 1 [7] was further mutagenized (I382M and D603H) and 
cloned into the pMSCV-puro vector, whereas the plasmids expressing isoform 1 bearing the 
mutations G439V and R445H were previously described [33]. Retrovirus production and infection 
were performed as described previously [34]. Plasmid (6μg/experiment) transfection of mouse 
embryonic fibroblasts (MEFs) was performed with Lipofectamine 3000 (Life Technologies) 
following the manufacturer’s instructions. 
 
2.2. Cells and culture conditions 
Skin fibroblast were derived, following informed consent, from five healthy donors, two DOA 
patients from two unrelated families with the I382M mutation, one patient with the G439V 
mutation, two related patients with the R445H mutation and two related patients with the D603H 
mutation. OPA1 gene localization of these mutations is reported in Table 1. All mutations were 
heterozygous and strictly co-segregated with individuals affected by optic atrophy in families with 
autosomal dominant inheritance.  
The range of age for patients’ fibroblasts is 24-59 years and for controls’ fibroblasts is 24-60 years, 
with 3 men and 2 women. Matching healthy donors with DOA patients for age and sex, the 
behavior of the five controls used was very similar and we decided to pull the controls together.  
Fibroblasts and MEFs were grown in DMEM containing 25mM glucose supplemented with 10% 
fetal bovine serum (FBS, South America, Gibco, Life Technologies), 2mM L–glutamine, 100U/ml 
penicillin and 100μg/ml streptomycin, in an incubator with a humidified atmosphere of 5% CO2 at 
37°C. For some experiments, cells were grown in glucose-free DMEM supplemented with 5mM 
galactose, 5mM sodium pyruvate and 5% FBS (DMEM-galactose).  
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2.3. Cellular ATP content 
The ATP content of cells in DMEM and during incubation in DMEM-galactose was measured by 
using the luciferin/luciferase assay, as previously described [35]. For statistical analysis, the 
Dunnett’s multiple comparison test was used. 
 
2.4. Mitochondrial network morphology 
Mitochondrial network morphology was analyzed as previously described in [36]. For statistical 
analysis, the Dunnett’s multiple comparison test was used. 
 
2.5. mtDNA content 
Quantification of human mtDNA copy number relative to nuclear DNA (nDNA) was performed, 
for both fibroblasts and muscle tissue, as previously described [37]. Quantification of mouse 
mtDNA copy number relative to nuclear DNA (nDNA) was carried out amplifying both mt-Nd1 
and β-Globin. Quantification was performed using the ΔΔ C(t) method. Primer sequences are 
reported in supplementary materials. For statistical analysis, the Dunnett’s multiple comparison test 
was used. 
 
2.6. Oxygen consumption rate 
The OCR was measured in XFe24 Extracellular Flux Analyzer (Seahorse Bioscience). Oxygen 
concentration were measured under basal condition and after injection of 1μM oligomycin, 1μM 
carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) or 5μM carbonyl cyanide m-
chlorophenyl hydrazone (CCCP), 1μM rotenone and 1μM antimycin A. The OCR values (pmoles 
O2/min) were normalized for protein content of each well, determined by the SRB assay. For 
statistical analysis, the Dunnett’s multiple comparison test was used. 
 
2.7. Western blotting 
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Cell lysates were prepared as previously described [24]. Aliquots were separated by 8% SDS–
PAGE and transferred onto nitrocellulose membranes (Bio-Rad). The membranes were incubated 
overnight at 4°C with the primary antibodies, then visualized using horseradish peroxidase-
conjugated secondary antibodies. The chemiluminescence signals were revealed using an ECL 
Western blotting kit and measured with Gel Logic 1500 Imaging System, Biosense. For statistical 
analysis, the Dunnett’s multiple comparison test was used. 
 
2.8. Respiratory supercomplexes and Complex V analysis 
Supercomplexes were separated by Blue Native-PAGE and analyzed as previously described [36]. 
For statistical analysis, the Dunnett’s multiple comparison test was used. 
 
2.9. cDNA Sequencing 
Total RNA was extracted from fibroblasts using the Pure Link RNA mini kit (Ambion) and treated 
with DNAseI enzyme (Sigma Aldrich). 1 ug of RNA was reverse transcribed by SuperScript VILO 
cDNA synthesis kit and analyzed by Sanger Sequencing, as previously reported [38]. 
 
2.10. Yeast strains and media 
The yeast strains used in this work were W303-1A mgm1 (MATa leu2-3, trp1-1, can1-100, ura3-
1, ade2–1, his3-11 mgm1::KanR), W303-1B mgm1 (MATα leu2-3, trp1-1, can1-100, ura3-1, ade 
2–1, his3-11 mgm1::KanR). The diploid DW1.1 was obtained by crossing W303-1A Δmgm1 and 
W303-1B Δmgm1 [32]. Synthetic complete medium (SC) contained 6.9g/l yeast nitrogen base 
without amino acids (Formedium), 1g/l drop-out mix according to Kaiser et al. [39]. YP medium 
contained 0.5% yeast extract (Formedium) and 1% peptone (Formedium); YPA medium was YP 
2X supplemented with 40mg/ml adenine base (Formedium). Carbon sources were added as 
indicated in the text. 
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2.11. Plasmids and construction of strains harboring CHIM3 wt and mutant alleles 
The plasmids used in this works are pFL38TEToff, pFL39TEToff, pFL36TEToff, pFL38MGM1 
and pFL39MGM1 [32]. chim3 mutant alleles were obtained by site-directed mutagenesis of a 
CHIM3 gene fragment, using the overlap extension technique [40]. In the first PCR, the forward 
primer TATACYC1Fw and specific reverse mutagenic primers were used (see primers list in the 
supplementary materials). In the second PCR, specific forward mutagenic primers and the reverse 
primer MGMOPACNotRv were employed. The final mutagenized products were obtained by using 
the overlapping PCR fragments as templates, with TATACYC1Fw and MGMOPACNotRv as 
external primers. Each final product was then digested with NotI and cloned in NotI-digested 
pFL39TEToff, obtaining pFL39TEToff plasmid-borne CHIM3
S298N
, CHIM3
G300E
, CHIM3
L331P
, 
CHIM3
G439V
, CHIM3
T449P
, CHIM3
S545R
, CHIM3
L593P
, CHIM3
D603H
, CHIM3
Q785R
 and CHIM3
V910D
 
mutant alleles. Mgm1 mutant alleles were obtained in the same way, using the forward primer 
MGM1FwSalI and the reverse primer MGM1RvSacI together with mutagenic primers reported in 
supplementary materials. Mutant and wt CHIM3 alleles were introduced in the mgm1 strain 
through the plasmid shuffling technique as previously reported [41]. 
 
2.12. Complementation studies in yeast 
Oxidative growth was evaluated by spotting serial cell dilutions of haploid strains (5x10
4
, 5x10
3
, 
5x10
2
 and 5x10
1
 cell/spot), in a total volume of 5μl on YP medium, supplemented with either 2% 
glucose or 2% glycerol after a 5-days incubation at 28°C. Diploid strains were diluted to an initial 
concentration of 5OD and then four 10-fold serial dilutions were made. A total volume of 5μl was 
spotted on solid SC medium, supplemented with 2% glucose or 1.5% glycerol-1.5% ethanol and the 
growth was evaluated after a 7-days incubation at 28°C. 
To measure the respiratory activity, diploid strains were pre-grown in SC supplemented with 2% 
galactose for 48h to limit the growth of petite cells. Cells were inoculated at a final concentration of 
0.08 OD/ml in SC supplemented with 0.6% glucose and grown until glucose was exhausted for 
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approximately 20h. The OCR was measured on whole cells using a Clark-type oxygen electrode 
(Oxygraph System Hansatech Instruments England) with 1ml of air-saturated respiration buffer 
(0.1M phthalate–KOH, pH 5.0), 10mM glucose at 30°C. The reaction started by addition of 20mg 
of wet-weight cells, as described previously [42,43]. For statistical analysis, the Dunnett’s multiple 
comparison test was used. 
 
2.13. Western blot analysis in yeast 
Total proteins from 4.8 OD (for haploid strains) and 3.6 OD (for diploid strains) of cells grown in 
SC supplemented with 0.6% glucose until exhaustion were extracted with the trichloroacetic acid 
(TCA) method by chilling the cells supplemented with 120 mM NaOH, 0.5% β-mercaptoethanol, 
650μM PMSF and 25% TCA on ice, then re-suspending the proteins in 60μl of Laemmli sample 
buffer at pH 6.8. 10μl of such suspension were separated by 8% SDS-PAGE, and electro-blotted 
onto nitrocellulose filters which were then incubated with anti-OPA1 and anti-VDAC antibodies. 
After incubation with anti-mouse secondary antibodies, the chemiluminescence signals were 
revealed using by ECL Western blotting substrate and measured with Imagequant Software (GE 
Healthcare). 
 
2.14. Mitochondrial morphology in yeast 
Haploid and diploid strains carrying CHIM3 or chim3 mutant alleles were transformed with 
pYEF1mtGFP [32]. Cells were pre-grown in SC medium supplemented with 2% glucose. After 
24h, the cells were transferred to SC medium supplemented with 0.15% glucose and 2% galactose 
in order to induce the expression of mtGFP, until the mid-log phase was reached. Once adjusted to 
1 OD/ml, the cells were observed with a Zeiss Observer 2.1 fluorescence microscope using a 630X 
magnification and images captured using an AxioVision Rel 4.8 software. Statistical analysis was 
performed using a 2 test on a 2x2 contingency table comparing the number of cells with 
filamentous mitochondria vs the number of cells with giant or fragmented mitochondria. 
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2.15. Template search, sequence alignments, and OPA1 homology modeling 
Template search was performed using the HHsearch method employed by the HHpred server 
(doi:10.1093/nar/gki408). The server performs up to eight iterative PSI-BLAST 
(doi:10.1093/nar/25.17.3389) searches through filtered versions of the non-redundant (nr) database 
from the NCBI. Using the final target alignment a profile hidden Markov model (HMM) 
(doi:10.1006/jmbi.1994.1104 ; doi:10.1093/bioinformatics/14.9.755) is calculated. Homologous 
templates are identified by searching through a weekly updated database containing HMMs for a 
representative subset of PDB sequences. Finally, HHsearch ranks database matches by the 
probability of the match to be homologous to the target sequence. This is useful to distinguish 
homologous from non-homologous matches. Excluding PDB structures that were not solved by 
using X-ray crystallography, HHpred identified the human myxovirus resistance protein 1 (MxA), 
an interferon-induced dynamin-like GTPase and the human Dynamin 1-like protein (DNM1L) as 
the best templates for OPA1. 
The target and template sequences were realigned using the Promals3D server 
(doi:10.1093/nar/gkn072) (see Supplementary Information for the results of the alignment). The 
obtained alignment was then used to calculate 100 models of OPA1 structure in the “open” 
conformation using the available crystal structures of human MxA [PDB code: 3SZR 
(doi:10.1016/j.immuni.2011.07.012)] and human DNM1L [PDB code: 4BEJ 
(doi:10.1038/emboj.2013.74)], using the Modeller 9.14 software (doi:10.1006/jmbi.1993.1626 P). 
The GDP molecule found in the human DNM1L structure was included in the modelling procedure. 
The best model was selected using the DOPE potential function built into Modeller 
(doi:10.1110/ps.062416606). A loop optimization routine was used to refine the regions that 
showed higher than average energy as calculated using the DOPE potential function. The final 
model was geometry optimized in the gas phase by using the UCSF Chimera 
(doi:10.1002/jcc.20084), the AMBER ff14SB force field (doi:10.1021/acs.jctc.5b00255), and the 
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AM1-BCC charges (doi:10.1002/jcc.10128). The stereochemical quality of the model structure was 
established using ProCheck (doi:10.1107/S0021889892009944). The results of this analysis 
confirm the reliability of the model structure. 
The template structure used to calculate the OPA1 model structure in the “closed” conformation 
was prepared by dividing the model in the “open” conformations in two parts, one formed by the 
GTPase domain the other formed by the helical domain. The two parts of the OPA1 model in the 
“open” conformation was then superimposed to the corresponding domains of the known structure 
of the bacterial dynamin like protein from Nostoc punctiforme [PDB code: 2J68 
(doi:10.1038/nature05312)]. This template structure was then used to calculate the model of OPA1 
in the “closed” conformation, following the same protocol described above. 
 
2.16. Reagents  
Antibodies: DRP1, MFN1, MFN2 (Abnova); NDUFA9, UQCRC2,  subunits CV, actin (Abcam); 
COX IV, SDHA (ThermoFisher Scientific); OPA1 (BD Biosciences); tubulin (Sigma-Aldrich); 
VDAC (Biovision); horseradish peroxidase-conjugated secondary antibodies (Jackson 
ImmunoResearch or Alexafluor). ECL western blotting kit from Biorad or Thermo Scientific 
Pierce. The other reagents from Sigma-Aldrich.  
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3. RESULTS 
3.1. Molecular and biochemical profile of fibroblasts bearing OPA1 mutations 
We have investigated fibroblasts derived from seven patients carrying four different OPA1 
missense mutations and five healthy donors. Three of these mutations were selected on the basis of 
their known clinical phenotypes, ranging from non-penetrant or very mild pure optic atrophy 
(I382M), to severe syndromic forms (G439V and R445H; see supplementary table 1 for description 
of patients’ clinical phenotypes). The fourth mutation, D603H, clinically expressed as pure DOA 
with severe visual loss, is here reported and fully characterized for the first time (Supplementary 
table 1 for description of patients’ clinical phenotypes). We have analyzed in detail these four 
mutations, intentionally including different clinical phenotypes (asymptomatic/mild optic atrophy, 
severe optic atrophy and syndromic optic atrophy), first in fibroblasts and then in other two cellular 
models generated “ad hoc”. 
The expression levels of MFN1, MFN2 and DRP1, the main proteins involved in the machinery of 
mitochondrial fusion and fission, were similar in control and DOA patients, whereas the amount of 
OPA1 was reduced in fibroblasts with the I382M, R445H and D603H mutations and slightly 
increased in G439V fibroblasts (Fig. 1A-B). Sequencing of retro-transcribed OPA1 mRNA in the 
same fibroblasts revealed the presence of both wild-type and mutated alleles (Fig. S1A), indicating 
that both the proteins were synthetized. Quantification of the relative amount of l- and s-forms 
revealed an increased l-/s-forms ratio for the G439V mutation only (Fig. 1C).  
We then studied the energetic competence of DOA patients’ fibroblasts, by evaluating initially the 
cellular ATP content during incubation in glucose-free DMEM containing galactose, a condition 
known to force cells to rely on OXPHOS for ATP synthesis. After 24h and 48h in DMEM-
galactose, the ATP levels of controls markedly increased (+60±15% and +40 ±17%, respectively), 
as a consequence of the shift from glycolytic to oxidative metabolism. Differently, all fibroblasts 
bearing OPA1 mutations were unable to rise the ATP content, being the differences from controls 
statistically significant at 24h only, when cells have not yet adjusted their metabolism to the change 
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of carbohydrate source (Fig. 2A). The same trend was evident by expressing the ATP values as 
nmol/mg of protein (Fig. S1B). A similar behavior was previously reported for DOA fibroblasts 
harboring OPA1 mutations leading to haploinsufficiency [24]. The oxygen consumption rate (OCR) 
was slightly reduced, without reaching statistical significance, in fibroblasts bearing the G439V 
mutation only (Fig. 2B-C), although the maximal/ATP-linked ratio and the respiratory control ratio 
(RCR) were similar in all cell lines (Fig. 2D-E). In DMEM-galactose the respiration was increased 
in all cell lines, but mutant fibroblasts were less efficient than controls, as evidenced by the non-
significant reduction of OCR traces and maximal/ATP-linked ratio (Fig. 2F-H). 
Semi-quantitative evaluation of the Complex I (CI) in gel activity (CI-IGA) and its densitometric 
analysis revealed that the amounts of isolated CI and of CI+III2 supercomplex were reduced in 
mutated fibroblasts compared to controls, except for the D603H mutation. The level of the most 
abundant CI+III2+IV supercomplex was similar to controls in all mutants, except for the D603H.  
The assembly of CV monomer was not compromised by any of the OPA1 mutations (Fig. 2I-J).  
All together these results indicate that despite mutants’ inability to increase the ATP content and 
respiration during the shift from glycolytic to oxidative metabolism, the supramolecular 
organization of OXPHOS complexes is not dramatically affected by OPA1 mutations in fibroblasts. 
Considering the OPA1 involvement in mtDNA maintenance [11,44], we also determined the 
mtDNA content. As reported in Fig. 3A, in fibroblasts with the I382M and D603H mutations the 
mtDNA copy number was similar to controls. Differently, the mtDNA amount was significantly 
reduced in R445H mutants and increased in fibroblasts with the G439V (Fig. 3A and Fig. S1C). 
The separate analysis of the two fibroblast cell lines carrying the R445H mutation revealed similar 
OPA1 levels (Fig. S1D) but different mtDNA content (Fig. S1E). Indeed, only the fibroblasts 
derived from patient II exhibited a marked reduction of mtDNA copy number, as also confirmed by 
analysis in the muscle biopsy (Fig. S1F). The mtDNA amount in the muscle biopsy of the G439V 
patient was normal (Fig. S1F).  
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The mitochondrial network morphology was then investigated by fluorescence microscopy. 
Representative images of fibroblasts incubated in DMEM-glucose or DMEM-galactose are reported 
in Fig. 3B. Quantitative analysis of mitochondrial morphology of fibroblasts incubated in DMEM-
glucose showed an almost complete filamentous mitochondrial network in controls and in cells with 
the I382M, whereas G439V and R445H mutations were associated with a slight increase of 
intermediate mitochondria. The D603H mutation presented a significant reduction of filamentous 
mitochondria and increase of intermediate mitochondria (Fig. 3C). In DMEM-galactose, the 
percentage of cells with fragmented mitochondria, which remained negligible in control fibroblasts, 
was variously increased by the presence of each OPA1 mutation, being statistically significant for 
the G439V and R445H mutations (60% and 40%, respectively, Fig. 3D). Again, D603H mutation 
presented a significant reduction of filamentous mitochondria and an increase of intermediate 
mitochondria (Fig. 3C). The results are summarized in table 2. 
All together these results underline the difficulty of studying the pathogenicity of an OPA1 
mutation and its molecular mechanism in patient fibroblasts that always present mild phenotypes, 
even when bearing severe mutations associated to DOA “plus”.  
 
3.2. Molecular and biochemical profile of MEF bearing OPA1 mutations  
We took advantage of Opa1-/- MEFs to express the OPA1 isoform 1 bearing each of the same four 
mutations analyzed in patients’ fibroblasts. This cell model, previously characterized by our group 
[36], allows to examine the specific effect of each mutation in the same nuclear background and 
without the confounder of the wt allele.  
Western blot analysis demonstrated that the balance of OPA1 l- and s-forms compared to ISO1 as 
well as the level of the other mitochondrial shaping proteins was not influenced by the different 
mutations (Fig. 4A-B).  
Because of the faster replication rate of MEFs compared to fibroblasts, the ATP content in DMEM-
galactose was measured after 16h and 24h of incubation. After 16h, MEFs bearing the G439V and 
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R445H mutations exhibited a significant reduction of ATP levels, similar to those of Opa1-/- 
MEFs, whereas MEFs with the other OPA1 mutations were similar to wt (Fig. 4C and S2A). The 
OCR traces are reported in Fig. 4D. Variable respiratory deficits were apparent in OPA1 mutated 
MEFs (Fig. 4D-E), ranging from a slight, not significant reduction of the maximal/ATP-linked 
respiration ratio apparent for I382M and D603H MEFs, to values similar to Opa1-/- MEFs in 
R445H and G439V MEFs (Fig. F). These two mutations presented also a non-significant reduction 
of RCR (Fig. 4G), whereas all mutants, with the exception of I382M, showed a significant shift 
toward glycolysis, as indicated by decreased OCR/ECAR ratio (Fig. 4H).  
The western blot analysis of OXPHOS subunits revealed reduced levels of NDUFA9 (CI), 
UQCRC2 (CIII) and COX IV (CIV) subunits in G439V and R445H MEFs (Fig. 5A-B). 
Concordantly, the semi-quantitative evaluation of CI-IGA and its densitometric analysis showed a 
reduction of isolated CI, and CI+III2 and CI+III2+IV supercomplexes in G439V and R445H MEFs 
compared to wt or ISO1, whereas D603H and I382M mutant MEFs displayed almost normal 
supramolecular assembly. Noticeably, the band at higher molecular weight corresponding to the 
CI+III2+IVn supercomplex was almost absent in MEFs bearing mutations in the GTPase domain 
(Fig. 5C-D). Immunodetection of CV revealed in G439V and R445H MEFs, similarly to Opa1-/- 
MEFs, a marked reduction of the band corresponding to the assembled monomer (F1-FO) and the 
appearance of two bands at lower molecular weight corresponding to free F1, indicating the 
presence of partially disassembled CV sub-complexes (Fig. 5C). These results underline a severe 
energetic defect associated with G439V and R445H mutations, whereas D603H only induces a 
slight energetic dysfunction, completely absent in I382M cells.  
It is noteworthy that the G439V and R445H mutations were associated with decreased mtDNA 
content, whereas the other two mutations exhibited values similar to those of wt and ISO1 MEFs 
(Fig. 6A). 
Representative images of mitochondrial network of MEFs bearing OPA1 mutations are reported in 
Fig. 6B. Quantification of network morphology showed that MEFs with the I382M mutation 
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presented a distribution similar to ISO1 MEFs, whereas the D603H induced both a significant 
increase in the percentage of cells with fragmented network and reduction of those with filamentous 
network. MEFs bearing the other two mutations exhibited the complete fragmentation of the 
mitochondrial network (Fig. 6C). The results are summarized in table 3. 
Overall these results evidenced that I382M mutation, associated with asymptomatic/very mild 
DOA, did not perturb mitochondrial morphology and mtDNA content, whereas D603H mutation, 
linked to pure DOA with severe visual loss, promoted mitochondrial fragmentation without any 
mtDNA reduction. Finally, G439V and R445H mutations, related with DOA “plus”, induced both 
mitochondrial fragmentation and significant mtDNA content decrease.   
To verify this emerging relationship between mtDNA and mitochondrial fragmentation as indicator 
of pure DOA or DOA “plus” outcome, we decided to examine three other mutations: R290Q (DOA 
“plus”; Supplementary table 1 for description of clinical phenotypes), S545R (pure DOA with 
severe optic atrophy [45]  or DOA “plus” [11,31]) and Q785R (pure DOA [38]) (see positions 
within the OPA1 protein and other details in Table 1).  
The expression of OPA1, MFN1, MFN2 and DRP1 proteins was not influenced by these three 
mutations (Fig. S2B). The mutation R290Q presented a significant decrease of mtDNA content (-30 
± 6%) and completely fragmented mitochondrial network (Fig S2C-E), whereas the S545R 
mutation exhibited a non-significant decline (-25 ± 10%) in presence of complete mitochondrial 
fragmentation (Fig S2C-E). The Q785R mutation did not change the mtDNA amount, still 
presenting a substantial increase in the percentage of cells with fragmented network (+60 ± 4%) 
(Fig S2C-E). Thus, the Q785R mutation acts as the D603H, both associated to pure DOA, the 
R290Q behaves as the DOA “plus” related G439V and R445H mutations, and the S545R has an 
borderline behavior between pure DOA with severe optic atrophy and DOA “plus”.  
 
3.3. Phenotypic profile of yeast strain harboring mutations in OPA1 
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The yeast S. cerevisiae has been extensively used as an in vivo model to study and validate the 
pathogenicity of mutations in genes involved in mitochondrial diseases, thanks to its ability to grow 
in absence of OXPHOS activity. Although yeast Mgm1 and OPA1 are orthologous, the sequence of 
the two proteins is poorly conserved, and the whole OPA1 cannot complement the deletion of 
MGM1 [32]. 
In order to validate OPA1 mutations in non-conserved residues, we have previously generated an 
MGM1/OPA1 chimeric construct (called CHIM3), encoding a protein composed of the N-terminal 
region of Mgm1, comprising the sequence required for mitochondrial import, and the 
transmembrane domain, fused to the catalytic region of OPA1, containing the GTPase, the middle 
and the GED domains [32].  
To acquire further insights on the consequences of the four missense mutations studied in 
fibroblasts and in MEFs on the OXPHOS phenotype, we exploited the CHIM3 allele. Two of the 
four mutations studied in fibroblasts and MEF models (I382M and R445H) were previously 
described in our system [32], and here re-analyzed adding the further G439V and D603H 
mutations.  
At first, the chim3 mutant alleles, obtained through mutagenic PCR, were introduced in the yeast 
centromeric (single copy) plasmid pFL39TEToff, under the strong yeast promoter CYC1 fused with 
seven repeats of the tetO operator cassettes. Since deletion of MGM1 makes the strain irreversibly 
devoid of mtDNA, CHIM3 alleles were introduced in the haploid W303-1B mgm1 strain 
transformed with the plasmid pFL38MGM1, which was subsequently lost by the plasmid shuffling 
technique in order to obtain a strain expressing only the CHIM3 alleles. The ability of the mutant 
alleles to complement the oxidative growth defect of the mgm1 strain was then evaluated by 
phenotypic analysis in medium supplemented with a non-fermentable carbon source and glucose as 
the control. All mutant strains, except the one harboring the I382M mutation, showed a respiratory 
deficient phenotype, confirming the severe pathological role of these mutations (Fig. 7A). 
CHIM3
I382M
 strain showed a slightly decreased growth (Fig. 7A) and reduction of respiratory 
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activity as well as of respiratory complexes activities [32], confirming its nature of hypomorphic 
allele. Furthermore, no mtDNA was present in each of the mutant strain, as determined by qPCR, 
except for the strain harboring the I382M mutation, for which a 20% decrease of mtDNA levels was 
observed (p<0,05 in a two-tailed t test) [32]. Western blot analysis showed that in all the mutant 
strains the total level of Chim3 was grossly similar, but all strains, except those carrying the I382M 
mutation, presented an unbalanced ratio of the l- and s-forms, with reduced amount of the s-forms 
compared to the CHIM3 wt strain, suggesting that the l-forms are not correctly processed (Fig. 7B 
and 7C). Finally, we observed the mitochondrial morphology of wt and mutant strains previously 
transformed with a plasmid harboring a GFP isoform localizing to mitochondria. As previously 
reported [32], we distinguished three major kinds of mitochondrial morphology: filamentous, 
fragmented and giant mitochondria (Fig. 7D). For each strain, we measured the percentage of cells 
harboring each of the three morphologies. We found that 35% of the CHIM3 cells had a filamentous 
morphology, whereas in the remaining cells mitochondria were fragmented or collapsed to form 
giant mitochondria. In the I382M strain, only the 20% of cells had filamentous mitochondria, 
whereas in all the other strains, including those transformed with the empty plasmid, all respiratory 
deficient, no cells with a filamentous morphology were observed (Fig. 7E). 
To test the dominance/recessivity of the mutations, diploid strains have been created. The diploid 
strain DW1.1/pFL38MGM1-pFL36TEToffCHIM3, deleted in both copies of genomic MGM1 and 
transformed with a plasmid copy of MGM1 and a plasmid copy of wt CHIM3, was transformed 
with the CHIM3 alleles cloned in pFL36TEToff. MGM1 was then lost by plasmid shuffling. The 
final strains contained either two copies of wild type CHIM3 (homoallelic diploid), a CHIM3 allele 
plus an empty plasmid (hemiallelic diploid) or a wild type CHIM3 and a mutated chim3 mutant 
copy (heteroallelic diploid). The growth phenotype of the diploid strains was evaluated by spot 
assay analysis on oxidative carbon sources (Fig. 7F). The growth of the heteroallelic strain 
containing the I382M mutation was similar to that of the homoallelic and hemiallelic strains. In all 
the remaining heteroallelic strains the growth was affected compared to the homoallelic one, 
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although at different extents, indicating that the mutations are dominant. In particular, R445H and 
D603H mutations strongly decreased the oxidative growth when in heterozygosis with CHIM3. 
Concordantly, the respiratory activity of heteroallelic strains carrying the mutations was reduced for 
all strains except for that bearing I382M mutation (Fig. 7G), similar to the results of growth 
analysis.  Finally, strains harboring G439V, R445H and D603G showed a significant decrease of 
cells with filamentous mitochondrial morphology, being again the strains R445H and D603G more 
affected (Fig. 7H). The results are summarized in table 4. 
 
3.4. Phenotypic profile of yeast strain harboring additional mutations in OPA1 
Thanks to the flexibility of yeast in studying mutations in OPA1, here we have also investigated 
other seven substitutions found in patients with both DOA or DOA “plus” phenotype and localized 
in the different OPA1 domains (see positions within the OPA1 protein and other details in Table 1). 
Concerning the haploid strains, we found that: (i) in all mutants, the oxidative growth was absent 
(Fig. 8A); (ii) no mtDNA was present, as measured with qPCR; (iii) the ratio of the l- and s-forms 
was unbalanced, although at different extent, except for strain harboring Q785R and V910D 
mutation (Fig. 8B and 8C); (iv) no filamentous mitochondrial morphology was observed  (Fig. 8D). 
Regarding the diploid strains, we found that most of the heteroallelic strains displayed a decreased 
oxidative growth, which was almost absent for strain harboring L593P mutation (Fig. 8E). On the 
contrary, in heteroallelic strains containing the Q785R and V910D mutations the growth was 
similar to that of the homoallelic one. The respiratory activity (Fig. 8F) and the mitochondrial 
morphology (Fig. 8G) were grossly congruent with the oxidative growth phenotype, suggesting that 
all the mutations, except the Q785R and the V910D ones, behaved as dominant negative.  
To ascertain whether these results were not influenced by the use of a chimeric gene, the S298N 
and I382M mutations, which involve conserved residues, were introduced at the corresponding 
position S241N and I322M in yeast Mgm1. The mgm1 haploid strain carrying the S241N mutation 
was unable to grow on respiratory carbon sources (data not shown), as observed for the chimeric 
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strain with the equivalent mutation (Fig. 3A), but not for the I322M mutation, as previously 
reported [32]. In heteroallelic condition, the mgm1
S241N
 allele behaved as dominant negative, with 
decreased oxidative growth and respiratory activity compared to both homoallelic (MGM1/MGM1) 
and hemiallelic (MGM1/empty plasmid) strains. On the contrary, heteroallelic strain harboring 
mgm1
I322M
, corresponding to the human mutation I382M, behaved as the homoallelic strain (Fig. 
S3A-B). 
 
3.5. OPA1 structural model and mutations mapping 
The structural determinants associated with the OPA1 mutations were analyzed through the 
calculations of structural models of OPA1. A homology model of human OPA1 was previously 
inferred on the basis of a distant homologue from the bacteria Nostoc punctiforme [11]. The recent 
release in the Protein Data Bank (PDB) of the structures of several OPA1 eukaryotic homologues, 
prompted us to develop a new OPA1 model. In particular, the new crystal structures feature the 
helical domain in a completely different conformation with respect to the GTPase domain, resulting 
in an elongated conformation (“open” conformation hereafter). We, thus, speculate that the bacterial 
OPA1 homologue from N. punctiforme structure shows the helical domain in a “close” 
conformation. Fig. 9A reports the homology models obtained for human OPA1 in the “open” and in 
the “close” conformations. 
The OPA1 mutations were mapped on the new structural models (Fig. 9B). The I382M and G439V 
are located near the G1 and G3 loops involved in the GTP binding and/or hydrolysis, conversely the 
R445H is positioned on the surface of the GTPase domain, in a region coming in contact with the 
helical domain in the “close” conformation, where it might impair the “closing” movement. The 
novel D603H sits in the “hinge” between the GTPase and the helical domains. An analogous 
structural mapping was performed for the other mutations analyzed in MEFs and in the yeast 
MGM1/OPA1 chimera: the R290Q, located in the first β-strand of the dynamin-type G domain, 
may impair the H-bond network or, more in general, the packing of this region. The S298N and 
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G300E mutations are in the G1 loop, the T499P is in contact with G1 loop and the S545R is in the 
GTP binding site. All these latter five mutations might alter GTP binding. The L593P and V910D 
mutations are located in the hinge of the two domains and, as D603H, may interfere with the helical 
domain motion. Finally, the Q785R mutation is positioned in the most external part of the helical 
domain, possibly hindering the interaction with another OPA1 protein during dimerization. 
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4. DISCUSSION 
This study provides the detailed characterization of the pathological consequences generated by a 
series of OPA1 mutations associated with a variety of clinical phenotypes, taking advantage of two 
novel cell models generated ad hoc to evaluate cellular dysfunctions strictly dependent on OPA1 
mutations: MEFs and yeasts.  These models display a clear-cut phenotype that provides, by 
complementary information, a quick definition of mutation’s pathogenicity, thus proving useful for 
patient’s diagnosis. Strikingly, some mutant alleles literally behave as null mutations (G439V, 
R445H and R290Q), when unopposed by the co-presence of the wt allele in MEFs, whereas at the 
opposite end a hypomorphic mutation such as I382M reveals only a slight damaging potential. 
4.1. Fibroblast model 
Fibroblasts from DOA patients are the commonest cell model used to date to analyze the effect of 
different OPA1 mutations, but suffer numerous limitations, such as great heterogeneity of 
phenotypes due to the individual nuclear and mitochondrial genomes variability and the presence of 
the wt allele. Furthermore, fibroblasts fail to display the features typically seen only in post-mitotic 
tissues, relevantly the mtDNA alterations (depletion/deletions). On the other hand, the experimental 
use of muscle tissue derived from patient’s biopsies is limited by the invasiveness of the procedure 
and the small amounts of material. Different degrees of energetic dysfunction, mitochondrial 
morphology and cristae alteration have been reported in DOA fibroblasts [11,21,23,24,30,46], 
particularly after enhancing the phenotype by metabolic stress conditions (DMEM-galactose) 
[24,30]. Furthermore, generation of primary fibroblast cultures takes a relatively long time and 
these cells suffer the disadvantage of a finite life span, undergoing replicative senescence.  
In this study the mtDNA content, energetics and network morphology were assessed in fibroblasts 
bearing three well know OPA1 mutations (I382M, G439V and R445H) and one new mutation 
(D603H).  Remarkably, the G439V and R445H mutations, associated with a similarly severe 
clinical phenotype, induced a substantial and opposite alteration in the mtDNA amount, a 
previously unrecognized feature in fibroblasts. The analysis of patient’s muscle bearing the G439V 
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mutation confirmed our previously reported result of an mtDNA content similar to controls [11]. 
Interestingly, for the R445H mutation, only the fibroblasts and corresponding muscle biopsy from 
patient II presented mtDNA depletion, whereas a normal amount of mtDNA was observed for 
patient I, notwithstanding the same reduction in OPA1 level in both cases. This observation 
suggests that other modifying factors might be influential. For example, considering the father-
daughter segregation of the R445H mutation, the mtDNA haplogroup differs, as well as other 
unknown nuclear variants, the age and gender. Considering the limited number of patients explored 
in this study, an appropriate large-scale investigation on this issue is warranted. From the energetic 
point of view, the mutations did not significantly influence the supercomplexes assembly, although 
a general and significant decrease in cellular ATP levels and respiration was detected after 
metabolic stress. In glucose, the basal and maximal mitochondrial respirations were slightly but not 
significantly reduced only with the G439V mutation, however both respiratory ratios were 
unaffected. Thus, although some energetic impairment was observed only after metabolic stress, a 
specific correlation with the mutation type could not be clearly identified. The only parameter that 
almost linearly correlated with the severity of patients’ clinical phenotype was the mitochondrial 
morphology in DMEM-galactose.  As summarized in Table 2, the overall evaluation of the five 
readouts shows that each mutation presents one, two or three dysfunctional parameters, not linearly 
correlated with the patient’s clinical conditions. 
4.2. MEFs model 
As a second model, the MEF lines stably expressing isoform 1 have proved also extremely useful, 
since the quick and easy insertion of the OPA1 missense mutations allowed for a detailed 
biochemical investigation of the dysfunctional phenotypes, which were enhanced as compared to 
fibroblasts and nicely correlated with the clinical severity observed in the patients. In fact, both 
G439V and R445H mutations induced drastic mtDNA depletion, impaired respiration, remarkable 
supercomplexes disorganization and complete mitochondrial network fragmentation, which are all 
in excellent agreement with the clinical severity of these DOA “plus” patients. The same 
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phenotypes were observed also for the R290Q and the G300E mutations [36], both associated with 
DOA “plus”. Opposite, the I382M mutation did not exhibit any significant dysfunction, except for 
its tendency to reduced respiration, in agreement with its role of mildly pathogenic or hypomorphic 
mutation. Interestingly, the novel D603H mutation, despite maintaining a normal mtDNA and ATP 
content, showed a slightly reduced respiration, a mild CV disassembly and a significant increase in 
mitochondrial network fragmentation, again in agreement with the intermediate clinical phenotype 
of these patients with pure DOA and severe visual dysfunction. Thus, as summarized in table 3, in 
MEFs model the number of defective hallmarks linearly increased with the severity of clinical 
phenotype of the mutation, being only one affected for the I382M mutation, three for the D603H 
mutation and five for the G439V and R445H mutations. While the Q785R mutation presented 
normal mtDNA and partially affected mitochondrial morphology, similar to the D603H mutation, 
the S545R mutation had an intermediate behavior, borderline across phenotypes. Indeed, the 
complete fragmentation of the mitochondrial network was associated with only a slight, non-
significant reduction of mtDNA amount, supporting a borderline nature of this variant, causing 
either DOA or DOA “plus” possibly depending on modulation of other genetic and/or 
environmental modifiers.  MEFs analysis suggests that a complete fragmentation of the 
mitochondrial network, in association with mtDNA depletion, hallmarks the DOA “plus” 
phenotype, whereas if these two parameters are mildly affected the final outcome is expected to be 
pure DOA. This hypothesis is represented in the scheme of figure 10.  
4.3. Yeast model 
Switching to the yeast model, by using a chimeric gene, the greatest advantage was the insight on 
the genetic mechanism of OPA1 mutations and the kind of dominance of the mutations. In fact, 
CHIM3 homoallelic and hemiallelic strains showed no difference in the respiratory phenotype, 
contrary to humans, likely due to a stronger promoter of the CHIM3 allele, which guarantees a 
sufficient, but not toxic, expression in the diploid strain too. However, the comparison of the 
haploid and diploid models may discern three types of mutant alleles. (i) If the haploid strain shows 
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a partially defective respiratory phenotype, i.e. a reduced oxidative growth and/or a reduced 
respiratory activity, and the heteroallelic strain behaves as the homo- and hemiallelic ones, then the 
mutant allele can be considered hypomorphic, as observed for I382M mutation. (ii) If the haploid 
strain displays no oxidative phenotype, i.e. is unable to grow on oxidative carbon sources, and the 
heteroallelic strain behaves as the hemiallelic one, then the mutant allele can be considered null, 
since it does not interfere with the activity of the wt allele. (iii) If the haploid strain displays no 
oxidative phenotype and the heteroallelic strain shows a decreased oxidative growth compared to 
the hemiallelic, the mutant allele can be considered antimorphic, resulting in a dominant negative 
phenotype.   
The current and our previous study [32] clearly revealed that all mutations associated with DOA or 
DOA “plus” phenotype cause, in haploid strain, the inability to grow on oxidative carbon sources 
due to loss of mtDNA. The only exception is the I382M, which is either associated with a very mild 
phenotype [47] or it has been proposed to act as a hypomorphic allele [16,19]. 
While human OPA1 nonsense mutations are associated in most cases with non-syndromic DOA due 
to haploinsufficiency as a genetic mechanism, missense mutations can be associated with both pure 
DOA or DOA “plus”, due to either haploinsufficiency or negative dominance, depending on the 
mutation [13,48]. Yeast analysis revealed that most mutations, with the exception of two, behave as 
partially dominant due to a negative dominance. The reduced oxidative growth and respiratory 
activity of heteroallelic strain suggest that the mutant isoform interferes with the wt protein. This 
result suggests two scenarios: (i) most of the missense mutations found in humans are per se 
partially dominant negative, and the severity of the phenotype as defined by pure DOA or DOA 
“plus”, depends on the degree of interference of the mutant protein on wt in affecting mtDNA 
maintenance and mitochondrial fragmentation. In addition, some missense mutations may 
adjunctively impinge on the stability of the mutant protein itself. (ii) Alternatively, most mutations 
are dominant and have the potential to cause a DOA “plus” phenotype, and the severity of disease 
depends on other factors, such as the co-presence of modifying variants in other genes, as well as 
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environmental factors or age/gender of the patients. This is the case for the S545R mutation, which 
was found associated with either DOA or DOA “plus” in different patients [13,31,45]. 
Intriguingly, we noticed that most mutations, including all the dominant negative ones, altered the 
relative amount of the l- and s-forms in the mutant haploid yeast strains compared with the wt, 
suggesting that such mutations can also impair the protein processing. In all cases, the levels of the 
s-form are decreased and, thus, the ratio of l- and s-forms is increased. By using both Opa1 null 
MEFs expressing different combination of OPA1 isoforms and OPA1 silenced HeLa cells, we have 
previously demonstrated that increased l- to s-forms ratio is associated with a highly fragmented 
mitochondrial network [36]. A similar phenotype was previously reported in yeast, where 
overexpression of the Mgm1 l-form, increasing the l- to s-forms ratio, lead to both loss of mtDNA 
and fragmentation of mitochondrial network [49]. Thus, increased l-/s-forms ratio in yeast could be 
used as an additional indicator of pathogenicity of the mutations. 
4.4. Models comparison 
The comparison of fibroblast and MEF results raises two observations deserving some further 
comments. First, there is a remarkable discrepancy in terms of OPA1 protein abundance, which is 
partially reduced in fibroblasts carrying the I382M, R445H and D603H mutations, whereas this is 
not affected in MEFs expressing the single mutant allele on isoform 1. The reduced amount of 
OPA1 protein was already noticed in other studies [15,50]. We envisage a possible explanation by 
hypothesizing that the interaction between mutant and wt protein may perturb OPA1 oligomers 
stability, favoring degradation. Second, we noticed that in patient’s derived fibroblasts CV and CI-
containing supercomplexes were properly assembled, at difference with MEFs carrying the most 
severe mutant mutations. We also determined a normal supramolecular organization in fibroblasts 
carrying OPA1 mutation causing haploinsufficiency mutations (Del Dotto and Zanna, unpublished 
results). These observations challenge the previously proposed relevance of supercomplex assembly 
as driving mechanism for the bioenergetics deficiency in DOA [51]. Considering that MEFs 
expressing the most severe OPA1 missense mutations displayed a significant perturbation of 
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supercomplexes organization, there must be a sufficient complementation by the wt allele 
overcoming this potentially harmful mechanism in patient‘s fibroblasts. This conundrum deserves 
further investigations. 
In yeast model most OPA1 mutations strongly compromise mtDNA content, mitochondrial 
morphology, oxidative growth and energetics, making difficult to identify the degrees of severity 
related to the different mutations. However, thanks to the chimeric gene, yeast modeling is excellent 
to determining whether a mutation is pathogenic or not and to evaluating its dominance/recessivity. 
Conversely, the MEFs model nicely defines the biochemical features, highlighting also different 
degrees of severity associated with the mutations, but does not inform on dominance/recessivity. 
These two models are therefore complementary, operating in parallel to uncover DOA 
pathophysiology.   
A further comparison of MEFs and haploid yeast strains showed that: (i) in both models, the mutant 
alleles bearing G439V and R445H mutations behaved as a null allele concerning mtDNA content, 
mitochondrial morphology and respiratory activity; (ii) MEF with I382M showed only a slightly 
altered phenotype, whereas yeast showed a slight but statistically significant alterations of mtDNA 
levels and mitochondrial morphology; (iii) for the other mutations, which behaved as null in the 
yeast model, there was a partial overlap with the phenotype found in MEFs, since the S545R 
mutation caused a complete mitochondrial fragmentation associated with a slight decrease of 
mtDNA levels, whereas D603H and Q785R mutations caused substantial increase in cells with 
fragmented network and, for the former mutation, a decrease of the OCR/ECAR ratio. 
Finally, the accurate mapping of all OPA1 mutations in the new OPA1 structural model showed that 
all mutations localized in the GTPase domain and involved in GTP binding/hydrolysis or GDP 
release may cause DOA or DOA “plus”. Interestingly, the mutations L593P, D603H and V910D, 
which appear harmless in the “open” conformation, reveal their detrimental potential only when 
considered in the “close” conformation, being located in the hinge of the two domains, thus 
interfering with the helical domain motion. 
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5. Conclusion 
In conclusion, our current results strongly support the combined analysis of human, MEF and yeast 
cell models for “deep phenotyping” of OPA1 mutations and comprehensive dissection of their 
mechanistic effects. These cell models hold great promises to developing new therapeutic 
interventions, taking advantage of the yeast model for powerful high throughput screening of 
molecules, whose efficiency could be then further validated in the mouse and human cell models.   
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LEGENDS TO FIGURES 
Figure 1: Fusion-fission proteins in OPA1 mutated fibroblasts.  
(A) Western blot of OPA1, MFN1, MFN2 and DRP1 expression levels; tubulin was used as a 
loading control. A representative experiment out of three is shown for MFN1, MFN2 and DRP1. A 
representative experiment out of six is shown for OPA1. Densitometric analysis of OPA1/tubulin 
(B) and OPA1 l-/s-forms ratio (C). Data, expressed as % of WT cells ratio, are means ± SEM (n=6). 
(B-C) For I382M, R445H and D603H mutations, data are means of two patients with the same 
mutation. In all panels * and ** denote values significantly different from the WT (p<0.05 and 
p<0.01, respectively) using Dunnett’s multiple comparison test. 
 
Figure 2: Energetic characterization of OPA1 mutated fibroblasts.  
(A) Cellular ATP levels after incubation for 24 and 48h in DMEM-galactose. Data, expressed as % 
of ATP content at time=0, are means ± SEM of WT (n=10), mutants (n=6) except for G439V (n=3). 
(B) OCR of fibroblasts in DMEM-glucose, expressed as pmoles O2/min normalized for protein 
content, under basal conditions and after injection of oligomycin (O), carbonyl cyanide 4-
(trifluoromethoxy) phenylhydrazone (FCCP; F), rotenone (R) and antimycin A (AA). (C) Basal, 
ATP-linked, maximal respiration and spare respiratory capacity. (D) Ratio between maximal and 
ATP-linked respiration. (E) Cell respiratory control ratio (RCR). (B-E) Data are means ± SEM of 
WT (n=10), mutants (n=6) except for G439V (n=5). (F) OCR of fibroblasts in DMEM-galactose 
(24h). The measure was performed in DMEM-galactose medium. (G) Basal, ATP-linked, maximal 
respiration and spare respiratory capacity. (H) Ratio between maximal and ATP-linked respiration. 
(F-H) Data are means ± SD of WT and mutants (n=3). (A-H) For I382M, R445H and D603H 
mutations, data are means of two patients with the same mutation. (I) CI IGA and western blot 
analysis of supercomplexes after BN-PAGE of digitonin-solubilized mitochondria. SDHA (CII) 
was used as a loading control. Supercomplexes composition and single complexes are indicated. 
SDS-PAGE of SDHA and VDAC used as a loading control. A representative experiment out of 
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three is shown. Bars indicate that one lane was removed from the blot. (J) Densitometric analysis of 
CI alone and CI-containing supercomplexes. Data, expressed as % of WT cells ratio, are means ± 
SD of three independent experiments.  
In all panels * and ** denote values significantly different from the WT (p<0.05 and p<0.01, 
respectively) using Dunnett’s multiple comparison test. 
 
Figure 3: mtDNA content and mitochondrial network morphology of OPA1 mutated 
fibroblasts. 
(A) mtDNA copy number. Data are means ± SEM of WT (n=10), mutants (n=6) except for G439V 
(n=3). (B) Representative images captured by fluorescence microscopy of mitochondrial network 
morphology of fibroblasts labeled with Mitotracker Red. Cell were incubated in DMEM-glucose 
(C) or for 24h in DMEM-galactose (D); 40 cells for each cell lines in duplicate (2 independent 
experiments) has been analyzed for controls (5 cell lines, 400 total cells) for each condition; 60 cells 
for each cell lines in triplicate (2 independent experiments) has been analyzed for mutants (7 cell 
lines; 180 total cells for the G439V mutation from one patient and 360 total cells for each of the 
other three mutations from six patients) for each condition. Cells were scored in three categories on 
the basis of mitochondrial network morphologies: cells with filamentous and interconnected 
network (filamentous), cells with short filamentous mitochondria (intermediate) and cells with 
fragmented mitochondria (fragmented). (A, C-D) For I382M, R445H and D603H mutations, data 
are the means of two patients with the same mutation. Data are means ± SEM of three independent 
experiments. In all panels *, ** and *** denote values significantly different from the WT (p<0.05, 
p<0.01 and p<0.001, respectively) using Dunnett’s multiple comparison test. 
 
Figure 4: Biochemical characterization of OPA1 mutated MEFs.  
(A) Western blot of OPA1, MFN1, MFN2 and DRP1 expression levels; tubulin was used as a 
loading control. A representative blot out of three is shown for MFN1, MFN2 and DRP1. A 
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representative blot out of eight is shown for OPA1. (B) Densitometric analysis of OPA1 l-/s-forms 
ratio. Data, expressed as % of ISO1 cells ratio, are means ± SEM (n=8). (C) Cellular ATP levels. 
Data are means ± SEM of WT and ISO1 (n=4) and all the other cell lines (n=3). (D) OCR of OPA1 
mutated MEFs, after the injection of oligomycin (O), carbonyl cyanide m-chlorophenyl hydrazone 
(CCCP; C), rotenone (R) and antimycin A (AA). (E) Basal, ATP-linked, maximal respiration and 
spare respiratory capacity. (F) Ratio between maximal and ATP-linked respiration. (G) Cell 
respiratory control ratio (RCR). (H) OCR and extracellular acidification rate (ECAR) ratio. (D-H) 
Data are means ± SD of Opa1-/- (n=2) and all the other cell lines (n=3). 
* and ** denote values significantly different from the WT (p<0.05 and p<0.01, respectively) using 
Dunnett’s multiple comparison test. 
 
Figure 5: OXPHOS subunits and supercomplexes analysis of OPA1 mutated MEFs. 
(A) Western blot of OXPHOS subunits expression levels; actin was used as a loading control. A 
representative experiment out of five is shown. (B) Densitometric analysis of OXPHOS subunits. 
Data, expressed as % of ISO1 cells ratio, are means ± SEM of five independent experiments.  
(C) CI IGA and Western blot analysis of supercomplexes by BN-PAGE. SDHA (CII) was used as a 
loading control. Supercomplexes composition and single complexes are indicated. SDS-PAGE of 
SDHA and VDAC used as a loading control. A representative experiment out of three is shown. 
Bars indicate that one lane was removed from the blot. (D) Densitometric analysis of CI and CI-
containing supercomplexes. Data, expressed as % of ISO1 cells ratio, are means ± SD of three 
independent experiments. * and ** denote values significantly different from the WT (p<0.05 and 
p<0.01, respectively) using Dunnett’s multiple comparison test.. 
 
Figure 6: mtDNA content and mitochondrial network morphology of OPA1 mutated MEFs. 
(A) mtDNA copy number. Data are means ± SEM of WT n=5, all the other cell lines n=6. 
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(B) Representative images captured by fluorescence microscopy of mitochondrial network 
morphology of MEFs incubated in DMEM-glucose, after labeling with Mitotracker Red (C) 60 
cells for WT, Opa1-/- and ISO1 in duplicate (2 independent experiments) has been analyzed (120 
cell for each lines); 40 cells for mutants cell lines in quadruplicate has been analyzed (160 cell for 
each mutants); cells were scored exactly as described in Fig. 3. Data are means ± SD. ** and *** 
denote values significantly different from the WT (p<0.01 and p<0.001, respectively) using 
Dunnett’s multiple comparison test.. 
 
Figure 7. Characterization of I382M, G439V, R445H and D603H mutations in yeast 
(A) Phenotypic analysis of haploid strains. Serial cell dilutions (5x10
4
, 5x10
3
, 5x10
2
 and 5x10
1
 
cell/spot) of W303-1B mgm1 strain transformed with CHIM3 wild type or mutant alleles were 
spotted on YP medium, supplemented with either 2% glucose and 2% glycerol. Pictures were taken 
after a 3-days incubation at 28°C. A representative experiment out of three independent clones is 
shown. (B) Western Blot analysis of OPA1 expression level. VDAC was used as loading control. A 
representative experiment out of two is shown. Bars indicate that one lane was removed from the 
blot. (C) Ratio between the l-form and the s-form normalized to the ratio observed in CHIM3. Data 
are means ± SD. (D) Representative example of the mitochondrial morphotypes in the investigated 
yeast strains. (E) Mitochondrial morphotypes percentage in haploid strains. 148 to 328 cells for 
each strain were observed at the microscope as reported in material and methods and classified as 
filamentous, fragmented or giant relative according to the mitochondrial morphology. ***(p<0.001) 
denotes significance relative to CHIM3 strain using a 2x2 2 test comparing filamentous vs 
fragmented+giant mitochondria. (F) Phenotypic analysis of diploid strains. Serial cell dilutions 
(5x10
4
, 5x10
3
, 5x10
2
 and 5x10
1
 cell/spot) of DW1.1 strain containing two copies of CHIM3 wild 
type (homoallelic diploid), a copy of CHIM3 wild type plus an empty plasmid (hemiallelic strain) 
or a CHIM3 wild type and a mutant chim3 copy (heteroallelic diploid) were spotted on YP medium, 
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supplemented with either 2% glucose or 1.5% glycerol-1.5% ethanol. Pictures were taken after a 5-
days incubation at 28°C. A representative experiment out of three independent clones is shown. (G)  
Respiratory activity of homo-, hemi and heteroallelic strains. Values are means ± SD of three to 
four independent experiments and have been normalized to the respiratory activity of the 
homoallelic diploid. *(p<0.05) and **(p<0.01) using Dunnett’s multiple comparison test. 
(H) Mitochondrial morphotypes percentage in diploid strains. 280 to 551 cells were classified as 
filamentous, fragmented or giant according to the mitochondrial morphology. ***(p<0.001) denotes 
significance relative to homoallelic strain using a 2x2 2 test comparing filamentous vs 
fragmented+giant mitochondria. 
 
Figure 8. Characterization of additional OPA1 mutations in yeast 
(A) Phenotypic analysis of haploid strains performed as in figure 7A. (B) Western Blot analysis of 
CHIM3 expression level as in figure 7B. A representative experiment out of two is shown. (C) 
Ratio between the l-/s-forms normalized to the ratio observed in CHIM3. Data are means ± SD. (D) 
Mitochondrial morphotypes percentage in haploid strains measured as in figure 7E, analyzing 143 
to 328 cells for each strain (E) Phenotypic analysis of diploid strains carried out as in figure 7F. (F) 
Respiratory activity of homo-, hemi and heteroallelic strains determined, as in figure 7G, on four to 
five independent clones. *(p<0.05), **(p<0.01) and ***(p<0.001) using Dunnett’s multiple 
comparison test. (G) Mitochondrial morphotypes percentage in diploid strains as detailed in figure 
7H, analyzing 288 to 737 cells for each strain. Measurement for the heteroallelic L593P could not 
be carried out due to the low growth level of this strain transformed with the mtGFP vector on SC 
medium. 
 
Figure 9: Modelling of OPA1 mutations.  
Ribbon diagram of OPA1 structural model (A) and localization of the mutations here analyzed (B). 
Left and right panels report OPA1 modelled in the “open” and “close” conformation, respectively. 
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In A, ribbons are colored from blue in the proximity of the N-terminus to red at the C-terminus, 
while in panel B the Cα of the mutated residues are reported with light blue spheres for the four 
mutations studied in fibroblasts and MEFs and green spheres for the mutations analyzed also in 
yeast and MEFs. 
 
Figure 10: Schematic view of the correlation between the amount of mtDNA and the 
mitochondrial fragmentation with final outcome in the severity of the DOA disease.  
In MEFs model, the increase of mitochondrial fragmentation without reduction of mtDNA copy 
number is associated with mutations causing pure DOA. The complete fragmentation of the 
mitochondrial network in association with a depletion of mtDNA hallmarks the DOA “plus” 
phenotype, whereas a severe alteration of network morphology with a mild decrease in mtDNA 
copy number characterizes mutations causing both pure DOA and DOA “plus”, located in a 
borderline zone modulated by modifier factors. 
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Table 1: Summary of OPA1 mutations with amino acid change, clinical phenotype and 
pathogenic prediction (CADD phred>20 are considered as pathogenic variants [52]). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
DNA 
MUTATION 
variant 1 
PROTEIN 
DOMAIN 
AMINOACID 
CHANGE 
isoform 1 
DISEASE CADD 
phred 
c.869G>A GTPase p.R290Q DOA “plus” 
30 
c.893G>A GTPase p.S298N DOA “plus” 
27.4 
c.899G>A GTPase p.G300E DOA 
27.7 
c.1146A>G GTPase p.I382M DOA 
24.4 
c.1316G>T GTPase p.G439V DOA “plus” 
30 
c.1334G>A GTPase p.R445H DOA “plus” 
34 
c.1345A>C GTPase p.T449P DOA “plus” 
28.1 
c.1635C>A Dynamin p.S545R DOA 
32 
c.1778T>C Dynamin p.L593P DOA 
29.9 
c.1807G>C Dynamin p.D603H DOA 
32 
c.2354A>G Dynamin p.Q785R DOA 
26.9 
c.2729T>A GED p.V910D DOA 
34 
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Table 2: Altered readouts of fibroblasts with the indicated OPA1 mutations 
MUTATIONS mtDNA ATP
a
 OCR
b
 RCS NETWORK
c
 ALTERED 
PHENOTYPES 
I382M No -60%* No No 20% 1 
G439V +50% * -80%* No No 60% 2 
R445H -30% * -60%* No No 50% 3 
D603H No -100%** No No 10% 1 
a
 Percent increase/decrease after 24h DMEM-galactose vs control fibroblasts 
b 
OCR in DMEM-glucose 
c
 Percentage of fibroblasts with fragmented mitochondria in DMEM-galactose 
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Table 3: Altered readouts of MEFs bearing the indicated OPA1 mutations 
MUTATIONS mtDNA ATP
a
 OCR 
Max/ATPlinked 
RCR 
OCR/ECAR 
RCS NETWORK
b
 ALTERED 
PHENOTYPES 
I382M No No No 
No 
No 
No No 0 
G439V -50% ** -80%* -50%** 
-50%* 
-60%* 
Yes 100% 5 
R445H -50%** -80%* -50%** 
-50%* 
-60%* 
Yes 100% 5 
D603H No No No 
No 
-40%* 
No 60% 2 
a
 Percent decrease after16h DMEM-galactose vs wt MEFs 
b
 Percentage of MEFs with fragmented mitochondria in DMEM-glucose 
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Table 4: Altered readouts of yeast bearing the indicated OPA1 mutations compared to 
haploid strain transformed with CHIM3 wt or homoallelic CHIM3 diploid strain 
MUTATIONS Haploid strain  
 mtDNAa OXIDATIVE 
GROWTHb 
RESPIRATORY 
ACTIVITYc 
NETWORKd LONG/SHORTe ALTERED 
PHENOTYPES 
I382M -20% Slightly decreased -25% 60% As wt 4 (slightly) 
G439V ND Absent NT 0% 4-fold 5 
R445H ND Absent NT 0% 2.5-fold 5 
D603H ND Absent NT 0% 2.5-fold 5 
  
MUTATIONS Diploid Strain  
 OXIDATIVE 
GROWTHf 
RESPIRATORY 
ACTIVITY 
NETWORKg DOMINANT/ 
RECESSIVEh 
ALTERED 
PHENOTYPES 
I382M As wt As wt As wt Recessive 0 
G439V Decreased -36%** 40% Negative dominant 3 
R445H Strongly 
decreased 
-40%** 18% Negative dominant 
 
3 
D603H Strongly 
decreased 
-44%** 4% Negative dominant 3 
 
a
 ND: not detectable by qPCR 
b
 Oxidative growth on YP medium supplemented with 2% glycerol. 
c
 NT: not tested due to inability to grow on oxidative carbon sources. 
d
 Percentage of cells with filamentous mitochondria compared to strain with haploid CHIM3 wt. 
e
 Fold increase 
f
 Oxidative growth on SD medium supplemented with ethanol and glycerol 
g
 Percentage of cells with filamentous mitochondria compared to homoallelic strain. 
h
 Based on the previous phenotypes on haploid and diploid strains as explained in the text. 
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Highlights 
 
Fibroblasts, MEFs and yeast define mechanism and pathogenicity of OPA1 mutations  
Yeast model provides information on OPA1 mutations dominance/recessivity 
MEFs model highlights different degrees of severity associated with OPA1 mutations 
MEFs and yeast models operate in parallel to uncover DOA pathophysiology   
mtDNA and mitochondrial fragmentation predict the severity of clinical phenotype 
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